Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Rare Diseases

Adenocarcinoma

Endometrial Neoplasms

Carcinoma

Carcinoma, Endometrioid

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Uterine Neoplasms

Genital Neoplasms, Female

Urogenital Neoplasms

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Ovarian Neoplasms

Ovarian Diseases

Adnexal Diseases

Gonadal Disorders

Endocrine System Diseases

Ovarian Cancer

Antineoplastic Agents

All Drugs and Chemicals

Pembrolizumab

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

SP-2577

Open-label study of SF-2577 plus pembrolizumab in advanced, recurrent small cell ovarian cancer as well as select additional ovarian and endometrial cancers within the SWI/SNF pathway.

This study is an open-label, non-randomized dose escalation and expansion study of the LSD inhibitor SP-2577 in combination with the anti PD- 1 antibody pembrolizumab in patients with advanced, recurrent small cell ovarian cancer of the hypercalcemic type (SCCOHT) as well as select additional ovarian and endometrial cancers with mutations in the genes within the SWI/SNF pathway (Ovarian Clear Cell Cancers (OCCC), Endometrioid Ovarian Cancers (EOC) and Endometrioid Endometrial Cancers (EEC).

Type of cancer being evaluated (ovarian and endometrial)

Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers

Pilot Feasibility and Efficacy Trial of a Novel Reversible LSD1 Inhibitor SP-2577 (Seclidemstat) Plus Pembrolizumab in Select SWI/SNF-mutant Gynecologic Cancers

Incidence of Adverse Events (AEs) as measured by NCI CTCAE version 5.0

Incidence of dose-limiting toxicities (DLTs) during the dose escalation phase

Percentage of participants with a best overall response of Complete Response (CR) or Partial Response (PR), as determined by Investigator according to Response Evaluation in Solid Tumors (RECIST) v 1.1

Percentage of participants with Disease Control (complete response, partial response, or stable disease) as determined by RECIST v1.1

Duration of Response as determined by the Investigator according to RECIST v1.1

Duration of Stable Disease as determined by the investigator according to RECIST v 1.1

Progression Free Survival (PFS) as determined by the Investigator according to RECIST v1.1

Overall Survival (OS) as determined by the Investigator according to RECIST v1.1

Plasma concentration of seclidemstat (SP-2577)

Proportion of circulating tumor DNA ( ctDNA) in peripheral blood and other body fluids e.g. ascitic fluid

Percentage of target inhibition by seclidemstat and pembrolizumab in tumor tissue biopsy specimens

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers	NCT04611139	SCCOHT Ovarian Clear C... Ovarian Endomet... Endometrial Can...	SP-2577 Pembrolizumab	18 Years -	HonorHealth Research Institute
Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers	NCT04611139	SCCOHT Ovarian Clear C... Ovarian Endomet... Endometrial Can...	SP-2577 Pembrolizumab	18 Years -	HonorHealth Research Institute

Spots Global Cancer Trial Database for sccoht

Every month we try and update this database with for sccoht cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for sccoht

Every month we try and update this database with for sccoht cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for sccoht cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.